Aardvark Therapeutics, Inc.
AARD
$8.22
-$0.30-3.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.39M | 1.03M | 1.50M | 1.50M | 696.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.45M | 5.09M | 4.12M | 4.12M | 2.23M |
| Operating Income | -9.45M | -5.09M | -4.12M | -4.12M | -2.23M |
| Income Before Tax | -8.78M | -4.18M | -3.81M | -3.81M | -2.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.78M | -4.18M | -3.81M | -3.81M | -2.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.78M | -4.18M | -3.81M | -3.81M | -2.04M |
| EBIT | -9.45M | -5.09M | -4.12M | -4.12M | -2.23M |
| EBITDA | -9.44M | -5.09M | -- | -- | -- |
| EPS Basic | -2.16 | -1.05 | -0.96 | -0.96 | -0.51 |
| Normalized Basic EPS | -1.34 | -0.64 | -0.59 | -0.59 | -0.33 |
| EPS Diluted | -2.16 | -1.05 | -0.96 | -0.96 | -0.51 |
| Normalized Diluted EPS | -1.34 | -0.64 | -0.59 | -0.59 | -0.33 |
| Average Basic Shares Outstanding | 4.06M | 3.99M | 3.97M | 3.97M | 3.97M |
| Average Diluted Shares Outstanding | 4.06M | 3.99M | 3.97M | 3.97M | 3.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |